We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Nixes Trevena’s Opioid in Tight Vote
FDA Advisory Committee Nixes Trevena’s Opioid in Tight Vote
An FDA advisory panel narrowly voted Thursday not to recommend approval of Trevena’s NDA for oliceridine, an opioid treatment for moderate-to-severe acute pain in adults.